Breast Cancer | Pharmacor | US/EU5 | 2015
Last Updated 29 October 2015
The treatment of breast cancer has a rich and diverse product pipeline and continues to be one of the most lucrative and active areas of research in oncology. However, the barriers to entry are high, owing to the well-established and effective therapies already available. Treatment is based on hormone receptor and HER2 expression, and successful therapies are often tailored to specific subpopulations. Substantial unmet need remains in the treatment of triple-negative breast cancer, for which no targeted therapy is approved.
Related Market Assessment Reports
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
